Aspirin-Functionalized Glycolide Copolymers for Biocompatible Shape Memory
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Amorphous polylactides (PLAs) used in medical applications face challenges such as brittleness, poor shape memory properties, and degradation-induced inflammation, which are not adequately addressed by existing copolymerization approaches that often require significant compositional changes or suppress critical early-stage inflammation.
Innovation Solution
The development of novel degradable thermoplastic copolymers incorporating a small percentage (5-10%) of aspirin-functionalized glycolide monomers, which enhance mechanical strength, shape memory performance, and toughness while mitigating inflammatory responses through dynamic hydrophobic interactions and controlled release of salicylic acid.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amorphous PLAs are used for minimally invasive surgical delivery, then they provide biocompatibility and degradability, but they exhibit brittleness and poor shape memory properties
Solution Approach 1:
The patent creates a composite polymer system by copolymerizing PLA with aspirin-functionalized monomers (AspGA). This composite structure combines the biocompatibility and degradability of PLA with the mechanical enhancement and anti-inflammatory properties of aspirin moieties, achieving both improved toughness and maintained biocompatibility without requiring significant compositional changes
2Strength
If copolymerization approaches are used to improve mechanical properties, then toughness and handling characteristics improve, but compositional changes exceed 50% non-PLA components
Solution Approach 1:
The patent applies partial action by incorporating only small amounts (5-10%) of aspirin-functionalized monomer into the PLA matrix. This partial incorporation is sufficient to achieve the desired mechanical enhancement and anti-inflammatory effects, avoiding the need for excessive compositional changes while still providing therapeutic benefit
3Object-affected harmful factors
If NSAIDs are administered to mitigate inflammatory responses, then degradation-induced inflammation is reduced, but critical early stage tissue repair is suppressed
Solution Approach 1:
The patent incorporates aspirin moieties directly into the polymer structure before implantation. These aspirin groups are released in advance during degradation to preemptively mitigate inflammatory responses caused by lactic acid, thereby protecting against harmful inflammation without suppressing the beneficial early-stage healing cascade
4Object-affected harmful factors
If hydrophilic anti-fouling surfaces are engineered to inhibit protein adhesion, then immune responses are reduced, but material properties change significantly
Solution Approach 1:
The patent extracts the anti-inflammatory function from the bulk material properties and places it in discrete aspirin moieties within the polymer structure. This allows the polymer to maintain its mechanical and compositional stability while the aspirin groups specifically target and mitigate inflammatory responses through their chemical activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The copolymers exhibit improved thermal, mechanical, and rheological properties, achieving gigapascal storage moduli and efficient shape recovery, while minimizing inflammatory responses without suppressing early acute inflammation, thus offering enhanced biocompatibility and biomedical application potential.
Implementation Method 1
The dynamic hydrophobic interactions among the aspirin pendants efficiently modulate the thermal, mechanical, rheological, and energy dissipative properties of the copolymer
Implementation Method 2
the concomitant hydrolysis of the aspirin pendants and the release of salicylic acid from the copolymer
Implementation Method 3
Degradable shape-memory polymers (SMPs), capable of being fixed into a temporary shape for minimally invasive surgical delivery and triggered to revert to a preprogrammed permanent shape by external stimuli
Data Source
AI summary
The invention provides novel compounds and polymers with pendant aspirin, and degradable and biocompatible compositions, medical devices and implants, and methods of making and use thereof.